- Borrowing a page from AstraZeneca's (AZN) playbook, Shire plc (SHPG) publishes its "Path to US$10B In Product Sales by 2020" as a clear message to AbbVie (ABBV) that it needs to substantially increase its offer if it wants the BOD to seriously consider it.
- Shire emphasizes its accelerating top-line growth, enhanced profitability, rich pipeline and total shareholder returns as proof that current management is on the right track and that Shire's future is bright continuing as an independent company.
Time for AbbVie to sharpen its pencil a fourth time
From other sites
Video at CNBC.com (Feb 11, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 14, 2015)
at CNBC.com (Jan 8, 2015)
at CNBC.com (Dec 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs